Please login to the form below

Not currently logged in
Email:
Password:

Biogen Idec signs brain research deal with Edinburgh University

Will identify potential treatments for multiple sclerosis and motor neurone disease

Biogen Idec building

US biotech Biogen Idec is to research potential new treatments for the neurodegenerative conditions multiple sclerosis and motor neurone disease in collaboration with the University of Edinburgh, Scotland.

The international partnership will see the two groups work together to improve understanding of the cell processes in the brain that lead to these conditions, both of which still have an unclear cause.

Set to last three years, the alliance will be based at Edinburgh BioQuarter – a biomedical-focused commercial collaboration between the University of Edinburgh, NHS Lothian and industry representatives.

Edinburgh BioQuarter is already home to several existing collaborations with life sciences companies, including a deal with GlaxoSmithKline (GSK) to develop medicines for acute pancreatitis; a fibrosis programme with Sweden's Galecto Biotech; and a deal with Belgium's Galapagos to test new drug compounds.

The group's key areas of research include regenerative medicine and inflammation, and Biogen will draw on this expertise to boost its own experience in the area, which includes big-selling multiple sclerosis drug Tysabri (natalizumab) and the recently launched treatment for relapsing-remitting multiple sclerosis Tecfidera (dimethyl fumarate).

“This landmark partnership is a brilliant example of academic-industrial collaboration in the field of discovery science,” said Siddharthan Chandran, professor of neurology at the University of Edinburgh's College of Medicine and Veterinary Medicine.

“Only by better understanding the biological processes behind these devastating diseases can we hope to discover new and effective therapies.”

Biogen's VP of neurology research Ken Rhodes was similarly positive about the potential for biotech companies to work with academia, with this latest agreement building on deals with Duke University, the HudsonAlpha Institute and the Myelin Repair Foundation.

“We have embraced academic collaborations as a part of our strategy to maintain a vibrant and innovative research organisation and better understand the underlying biology of neurodegenerative disease,” said Rhodes.

19th July 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Easier access to medicines in the UK?
Cutting through the NICE value-based assessment consultation to find out what’s at stake...
Exploring MINT: Part 3 - Nigeria
In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria....
BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....